TATVA Tatva Chintan Pharma Chem Q3 FY26 results (Oct–Dec 2025) and concall
Tatva Chintan delivered a strong Q3 FY26, with operating revenue growing 53% YoY to INR1,313 million and EBITDA surging 261% YoY to INR255 million, primarily driven by robust performance in Pharma & Agro Intermediates and Specialty Chemicals, and Structured Directing Agents. The company is actively advancing its capacity expansion, with a new agro intermediate plant nearing commercialization and plans for a greenfield plant at Jolva. Despite some sequential declines in certain segments and ongoing geopolitical uncertainties, management expressed confidence in the chemical industry's stabilizat
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 52.3% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|
| Revenue | 86 | 108 | 117 | 124 | 131 +52% |
| EBITDA | 7 | 9 | 17 | 22 | 25 +257% |
| Net profit | 0 | 1 | 7 | 10 | 15 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
